GH Research plc GHRS
$19.82
▲ +2.23% 24H
About
GH Research plc is a clinical-stage biopharmaceutical company dedicated to transforming treatments for psychiatric and neurological disorders. It specializes in developing novel, proprietary mebufotenin (5-methoxy-N,N-dimethyltryptamine, or 5-MeO-DMT) product candidates, with GH001 as its lead pulmonary inhalation form…
SectorHealthcare
ExchangeNASDAQ
IndustryBiotechnology
CountryIreland
Employees73
TickerGHRS
Statistics
Market Cap$1.23B
Revenue (TTM)—
Net Income—
Net Margin—
EPS—
P/E-27.54
P/S—
P/B4.87
EV/EBITDA-15.24
ROE-19.7%
Dividend Yield—
Price$19.82
Data: Twelve Data · Revenue = mcap / P/S